BUZZ — Vanda Pharma shares slip as trial failure halts anxiety drug program

* Shares of Vanda Pharmaceuticals fall 1.7% to $4.15 premarket * Co said late on Wednesday its experimental anxiety drug, VQW-765, failed to meet the main goal of a late-stage study * The drug did not reduce stress levels compared to placebo during a public-speaking stress test * Vanda puts the VQW-765 development program on hold while it reviews the full study data * The trial miss "adds pressure to the rest of the portfolio," Oppenheimer analysts said, adding that investors may now apply a "higher bar" to other Vanda programs * As of last close, stock down 52% YTD (Reporting by Kamal Choudhury in Bengaluru) ((Kamal.Choudhury@thomsonreuters.com;)